Pharma News

The day in pharma, read in minutes.

Updated Nov 19, 2026

Latest news

11 stories
NewsNew

Biocon Secures EU Approval for Pertuzumab Biosimilar

Biocon secures EMA marketing authorisation for a pertuzumab biosimilar covering HER2-positive breast cancer across multiple disease stages in the EU.

Vaibhavi M.Nov 19, 2026Read more
Biocon Secures EU Approval for Pertuzumab Biosimilar
NewsNew

Pfizer Signs $2.63B Starna CAR-T Deal for Autoimmune Disease

Pfizer's $2.63B CAR-T licensing deal with Starna Therapeutics raises immediate questions for cell therapy CDMOs on GMP readiness and manufacturing capacity.

Vaibhavi M.Nov 19, 2026Read more
Pfizer Signs $2.63B Starna CAR-T Deal for Autoimmune Disease
News

Evotec Achieves IND Acceptance for CELMoD Molecular Glue Degrader

Evotec and BMS secure a second FDA IND acceptance for a CELMoD degrader, with Phase 1 entry targeted for 2027.

Vaibhavi M.Nov 19, 2026Read more
Evotec Achieves IND Acceptance for CELMoD Molecular Glue Degrader
News

Genzyme Wins FDA Approval for Infilbray in Type 3 Gaucher

FDA approves Infilbray (venglustat) for GD3 neurological symptoms, raising CNS-penetrant GMP and process validation considerations for Genzyme.

Vaibhavi M.Nov 19, 2026Read more
Genzyme Wins FDA Approval for Infilbray in Type 3 Gaucher
News

EktaH Advances NKS-3 Obesity Drug into Phase IIa

EktaH enrolls first patient in Phase IIa obesity trial in Tunisia, backed by €2.4M in new funding for NKS-3.

Vaibhavi M.Nov 18, 2026Read more
EktaH Advances NKS-3 Obesity Drug into Phase IIa
News

Innate Pharma Reports Phase 1 Results for IPH4502 ADC

Innate Pharma's IPH4502 Phase 1 data show linker stability signal and 33% ORR at MTD; dose optimization begins H1 2027.

Vaibhavi M.Nov 18, 2026Read more
Innate Pharma Reports Phase 1 Results for IPH4502 ADC
News

Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib

Merck halts Phase 3 BELLWAVE-011 for nemtabrutinib after an external DMC finds risk-benefit balance unfavorable, closing a late-stage BTK inhibitor program.

Vaibhavi M.Nov 18, 2026Read more
Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib
News

FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA

FDA's GRDP expands to all NMEs and BLAs in January 2027, requiring a 10-day post-approval request window and confirmed foreign-market submissions.

Vaibhavi M.Nov 18, 2026Read more
FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA
News

FDA Draft Guidance Sets Bayesian Methods for Drug Trials

FDA draft guidance FDA-2025-D-3217 defines acceptable Bayesian methodology use for primary inference in NDA, BLA, and IND clinical trial submissions.

Vaibhavi M.Nov 18, 2026Read more
FDA Draft Guidance Sets Bayesian Methods for Drug Trials
News

Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC

FDA grants neladalkib accelerated approval for ALK-positive NSCLC, triggering confirmatory trial and manufacturing scale-up obligations for Nuvalent.

Vaibhavi M.Nov 18, 2026Read more
Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC
News

Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC

FDA approves Lembaz for infantile-onset NPC using external control survival data, setting a precedent for rare disease regulatory strategy.

Vaibhavi M.Nov 18, 2026Read more
Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC